New oral drug tested for aggressive leukemia that has returned
NCT ID NCT04872478
Summary
This early-stage trial is testing the safety and proper dosing of an experimental oral medication called MRX-2843. It is for adolescents and adults whose acute leukemia has come back or has not responded to previous treatments. The main goal is to find the highest dose that can be given safely and to see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University - WINSHIP Cancer Center
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Emory University, Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.